Login to Your Account



Mylan, Momenta strike $245M biosimilars deal

By Michael Fitzhugh
Staff Writer

Friday, January 8, 2016

Mylan NV and Momenta Pharmaceuticals Inc. agreed to work together to develop, manufacture and commercialize six of Momenta's current biosimilar candidates under an exclusive new deal.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription